In this systematic review published in Cancer, researchers looked at the associations of the efficacy of each approved treatment regimen for relapsed and/or refractory multiple myeloma with adverse events (AEs) and the total cost per cycle compared with a Bayesian network meta-analysis of phase III randomized controlled trials (RCTs).
The researchers indicated that the results of the network meta-analysis could provide additional guidance for the decision-making process when clinicians are deciding on the most appropriate regimen for relapsed and/or refractory multiple myeloma.
“To our knowledge, this is the first [network meta-analysis] that has indirectly evaluated the efficacy, safety, and total treatment cost of a myriad of approved [relapsed and/or refractory multiple myeloma] regimens using phase III RCTs,” the authors wrote.
Using Scopus, Cochrane, PubMed Publisher,…
